EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial

Deng Pan, Lu Liang, Qian Zhao, Jianwu Zheng, Houyong Zhu, Yu Wang, Cheng Bao, Tielong Chen

Frontiers in Cardiovascular Medicine · 29.05.2026 · 13

DOI: 10.3389/fcvm.2026.1723249 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 29.05.2026. Verfasst von Deng Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

FangJiHuangQi Granules (FJHQG) is a Chinese patent medicine that alleviates heart failure (HF) symptoms derived from the formula FangJiHuangQi decoction. Previous experiment has revealed that FangJiHuangQi decoction alleviated pathological injury in rats with HF. This trial intends to evaluate FJHQG's efficacy and safety as a complementary therapy in addition to conventional drug treatment.

Methods

This trial is a randomized, double-blind, placebo-controlled study that recruits 100 patients with HF. Participants will be randomly assigned into the intervention and control groups ( n = 50 for each group). For a duration of 12 weeks, FJHQG will be administered to the intervention group, and the control group will receive standard therapy plus placebo. The primary outcome of the trial is the changes of six-minute walk test at week 24. Secondary outcomes include BNP levels, NYHA classification, major adverse cardiovascular events (MACE), and KCCQ quality of life scales. Other exploratory assessments at the beginning and after a 12-week period will include fluid balance, symptom score scales, echocardiograms, diuretic consumption, and biochemical indices. Monitoring of MACE will continue until 12 weeks after drug discontinuation.

Discussion

This study will evaluate the efficacy and safety of FJHQG in HF treatment and to examine potential mechanisms, offering new insights into HF treatment. Clinical Trial Registration ChiCTR.org , ChiCTR2400080029.

Schlagwörter

Stichwörter der Autor:innen

clinical trialfangJiHuangQi granuleheart failureprotocoltraditional Chinese medicine

Autor:innen und Institutionen

  • Department of Cardiology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.

Zitieren

APA

Pan, D., Liang, L., Zhao, Q., Zheng, J., Zhu, H., Wang, Y., Bao, C., & Chen, T. (2026). Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1723249

Vancouver

Pan D, Liang L, Zhao Q, Zheng J, Zhu H, Wang Y, et al. Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1723249

BibTeX
@article{Pan2026,
  author = {Pan, Deng and Liang, Lu and Zhao, Qian and Zheng, Jianwu and Zhu, Houyong and Wang, Yu and Bao, Cheng and Chen, Tielong},
  title = {Efficacy and safety of FangJiHuangQi granule in patients with heart failure: a protocol of randomized, placebo-controlled trial},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1723249}
}
Kostenlos starten →